Home > Healthcare > Medical Devices > Diagnostic Devices > Cancer Biopsy Market

Cancer Biopsy Market Share

Report ID: GMI10995
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Cancer Biopsy Market Share

The market is characterized by intense competition among major players focusing on advancements in diagnostic technologies and innovative biopsy solutions. Key strategies include significant investment in research and development to enhance the accuracy and effectiveness of biopsy techniques, strategic partnerships and acquisitions to expand market reach, and collaborations with healthcare providers and research institutions to drive technological innovations and improve patient outcomes.

Cancer Biopsy Market Companies

Few of the prominent players operating in the cancer biopsy industry include:

ANGLE plc
BD (Becton, Dickinson and Company)
Biodesix (Integrated Diagnostics)
Chronix Biomedical, Inc (Oncocyte Corporation )
Devicor Medical Products, Inc.
GRAIL, Inc.
Hologic, Inc.
Illumina, Inc.
IZI Medical Products
Lucence Health Inc.
Myriad Genetics, Inc.
Oncimmune Holdings PLC
Personal Genome Diagnostics Inc.
QIAGEN N.V.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cancer biopsy market size was USD 21.5 billion in 2023 and is expected to register 8.4% CAGR from 2024-2032 due to increasing prevalence of cancer and advancements in cancer diagnostic technologies, including biopsies worldwide.

Cancer biopsy industry from the tissue biopsy segment is expected to register 8.3% CAGR from 2024-2032 due to its preference as the gold standard for cancer diagnosis, providing highly accurate and reliable results.

The U.S. cancer biopsy industry is expected to reach USD 18 billion by 2032 due to advanced healthcare infrastructure, significant investment in research and development, and the presence of leading medical device companies in the Country.

ANGLE plc, Devicor Medical Products, Inc., GRAIL, Inc., Hologic, Inc., Illumina, Inc., IZI Medical Products, Lucence Health Inc., Myriad Genetics, Inc., Oncimmune Holdings PLC, Personal Genome Diagnostics Inc., and QIAGEN N.V., are some of the major cancer biopsy companies worldwide.